CMC Advisory

CMC Strategy for Therapeutic Developers

Advanced therapy programs require disciplined coordination across process development, manufacturing partners, and regulatory timelines.

DB Biologics supports

  • Clinical manufacturing readiness planning

  • CDMO evaluation and selection

  • Long term scalability considerations

  • Cross functional CMC planning

  • Risk assessment across manufacturing workflows

Ecosystem-Level Strategic Insight

This cross-sector experience informs a practical, real-world understanding of how manufacturing and testing capabilities are evaluated, selected, and deployed in clinical programs

In addition to advising therapeutic developers, DB Biologics works with

  • CDMOs on commercial positioning and differentiation

  • Enabling technology providers and analytical testing companies on market strategy and commercial penetration